Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497 is registered in ClinicalTrials.gov with Crescent Biopharma, Inc. as lead sponsor.

NCT NCT07335497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07335497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Crescent Biopharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 17, 2026
Completion date
February 28, 2029
Enrollment
290 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced / metastatic solid tumors